Mersacidin eradicates methicillin-resistant Staphylococcus aureus (MRSA) in a mouse rhinitis model

Journal of Antimicrobial Chemotherapy

Volumn 54, Issue 3, 2004, Pages 648-653

  Kruszewska, Danuta ^a   Sahl, Hans Georg ^b   Bierbaum, Gabriele ^b   Pag, Ulrike ^b   Hynes, Sean O ^a   Ljungh, Åsa ^a  

^a LUND UNIVERSITY   (Sweden)

^b UNIVERSITY OF BONN   (Germany)

Author keywords

Lantibiotics; Mouse model; MRSA nasal carriage

Indexed keywords

HYDROCORTISONE; INTERLEUKIN 1BETA; MERSACIDIN; METICILLIN; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBACTERIAL ACTIVITY; ARTICLE; BACTEREMIA; BACTERIAL COLONIZATION; BACTERIAL TRANSMISSION; BACTERIUM DETECTION; BLOOD SAMPLING; CONTROLLED STUDY; DRUG EFFICACY; DRUG STRUCTURE; ERADICATION THERAPY; EXPERIMENTAL INFECTION; FEMALE; HEPATITIS; IN VITRO STUDY; INOCULATION; KIDNEY INFECTION; LUNG INFECTION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MOUSE; NONHUMAN; NOSE INFECTION; NOSE MUCOSA; RHINITIS; SERUM BACTERICIDAL ACTIVITY; SPLEEN; SUSPENSION;

ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIOCINS; FEMALE; HYDROCORTISONE; INTERLEUKIN-1; LYMPHOTOXIN-ALPHA; METHICILLIN RESISTANCE; MICE; MICE, INBRED BALB C; MICROBIAL SENSITIVITY TESTS; NASAL MUCOSA; PEPTIDES; REPRODUCIBILITY OF RESULTS; RHINITIS; SERUM BACTERICIDAL TEST; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS;

EID: 4644313503     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/dkh387     Document Type: Article

References (36)

1. Chambers, H. F. (2001). The changing epidemiology of Staphylococcus aureus? Emerging Infectious Diseases 7, 178-82.
2. Lowy, F. D. (1998). Staphylococcus infections. New England Journal of Medicine 339, 520-32.
3. Bozdogan, B., Duygu, E., Whitener, C. et al. (2003). Antibacterial susceptibility of a vancomycin-resistant Staphylococcus aureus strain isolated at the Hershey Medical Center. Journal of Antimicrobial Chemotherapy 52, 864-8.
4. Chang, S., Sievert, D. M., Hageman, J. C. et al. (2003). Infection with vancomycin resistant Staphylococcus aureus containing the van A resistance gene. New England Journal of Medicine 348, 1342-7.
5. Kluytmans, J., van Belkum, A. & Verbrugh, H. (1997). Nasal carriage of Staphylococcus aureus: epidemiology, underlying mechanisms, and associated risks. Clinical Microbiology Reviews 10, 505-20.
6. von Eiff, C., Becker, K., Machka, K. et al. (2001). Nasal carriage as a source of Staphylococcus aureus bacteremia. Study Group. New England Journal of Medicine 344, 11-6.
7. Peacock, S. J., de Silva, I. & Lowy, F. D. (2001). What determines nasal carriage of Staphylococcus aureus? Trends in Microbiology 9, 605-10.
8. Cole, A. M., Tahk, S., Oren, A. et al. (2001). Determinants of Staphylococcus aureus nasal carriage. Clinical and Diagnostic Laboratory Immunology 8, 1064-9.
9. Bierbaum, G., Brotz, H., Koller, K. P. et al. (1995). Cloning, sequencing and production of the lantibiotic mersacidin. FEMS Microbiology Letters 127, 121-6.
10. Altena, K., Guder, A., Cramer, C. et al. (2000). Biosynthesis of the lantibiotic mersacidin: organization of a type B lantibiotic gene cluster. Applied and Environmental Microbiology 66, 2565-71.
11. Guder, A., Wiedemann, I. & Sahl, H. G. (2000). Posttranslationally modified bacteriocins - the lantibiotics. Biopolymers 55, 62-73.
12. Niu, W. W. & Neu, H. C. (1991). Activity of mersacidin, a novel peptide, compared with that of vancomycin, teicoplanin, and daptomycin. Antimicrobial Agents and Chemotherapy 35, 998-1000.
13. Hoffmann, A., Pag, U., Wiedemann, I. et al. (2002). Combination of antibiotic mechanisms in lantibiotics. II Farmaco 57, 685-91.
14. Pag, U. & Sahl, H. G. (2002). Multiple activities in lantibiotics models for the design of novel antibiotics? Current Pharmaceutical Design 8, 815-33.
15. Brotz, H., Bierbaum, G., Reynolds, P. E. et al. (1997). The lantibiotic mersacidin inhibits peptidoglycan biosynthesis at the level of transglycosylation. European Journal of Biochemistry 246, 193-9.
16. Brotz, H., Bierbaum, G., Markus, A. et al. (1995). Mode of action of the lantibiotic mersacidin: inhibition of peptidoglycan biosynthesis via a novel mechanism? Antimicrobial Agents and Chemotherapy 39, 714-9.
17. Brotz, H., Bierbaum, G., Leopold, K. et al. (1998). The lantibiotic mersacidin inhibits peptidoglycan synthesis by targeting lipid II. Antimicrobial Agents and Chemotherapy 42, 154-60.
18. Chatterjee, S., Chatterjee, D. K., Jani, R. H. et al. (1992). Mersacidin, a new antibiotic from Bacillus. Fermentation, isolation, purification and chemical characterization. Journal of Antibiotics (Tokyo) 45, 832-8.
19. Molitor, E., Kluczny, C., Brotz, H. et al. (1996). Effects of the lantibiotic mersacidin on the morphology of staphylococci. Zentralblatt fur Bakteriologie 284, 318-28.
20. Barrett, M. S., Wenzel, R. P. & Jones, R. N. (1992). In vitro activity of mersacidin (M87-1551), an investigational peptide antibiotic tested against gram-positive bloodstream isolates. Diagnostic Microbiology and Infectious Disease 15, 641-4.
21. Chatterjee, S., Chatterjee, D. K., Jani, R. H. et al. (1992). Mersacidin, a new antibiotic from Bacillus. In vitro and in vivo antibacterial activity. Journal of Antibiotics (Tokyo) 45, 839-45.
22. Kloos, W. E. & Bannerman, T. L. (1999). Staphylococcus and Micrococcus. In Manual of Clinical Microbiology, 7th edn (Murray, P. R., Baron, E. J., Pfaller, M. A. et al. Eds) pp. 282-98. American Society for Microbiology, Washington, DC, USA.
23. du Toit, E. A. & Rautenbach, M. (2002). A sensitive standardised micro-gel well diffusion assay for the determination of antimicrobial activity. Journal of Microbiological Methods 42, 159-65.
24. National Committee for Clinical Laboratory Standards (1993). Methods for Dilution Antibacterial Susceptibility Tests for Bacteria that Growth Aerobically: Approved Standard M7-A3. NCCLS, Villanova, PA, USA.
25. Herigstad, B., Hamilton, M. & Heersink, J. (2001). How to optimise the drop plate method for enumerating bacteria. Journal of Microbiological Methods 44, 121-9.
26. Kiser, K. B., Cantey-Kiser, J. M. & Lee, J. C. (1999). Development and characterization of a Staphylococcus aureus nasal colonization model in mice. Infection and Immunity 67, 5001-6.
27. Kruszewska, D., Lan, J., Lorca, G. et al. (2002). Selection of lactic acid bacteria as probiotic strains by in vitro tests. Microecology and Therapy 29, 37-49.
28. Hudson, I. R. (1994). The efficacy of intranasal mupirocin in the prevention of staphylococcal infections: a review of recent experience. Journal of Hospital Infections 27, 81-98.
29. Cookson, B. D. (1998). The emergence of mupirocin resistance: a challenge to infection control and antibiotic prescribing practice. Antimicrobial Agents and Chemotherapy 41, 11-8.
30. Hiramatsu, K., Okuma, K., Ma, X. X. et al. (2002). New trends in Staphylococcus aureus infections: glycopeptide resistance in hospital and methicillin resistance in the community. Current Opinion in Infectious Diseases 15, 407-13.
31. Watanabe, H., Masaki, H., Asoh, N. et al. (2001). Low concentrations of mupirocin in the pharynx following intranasal application may contribute to mupirocin resistance in methicillin-resistant Staphylococcus aureus. Journal of Clinical Microbiology 39, 3775-7.
32. Leski, A. T., Gniadkowski, M., Skoczynska, A. et al. (1999). Outbreak of mupirocin-resistant staphylococci in a hospital in Warsaw, Poland, due to plasmid transmission and clonal spread of several strains. Journal of Clinical Microbiology 37, 2781-8.
33. Hechard, Y. & Sahl, H. G. (2002). Mode of action of modified and unmodified bacteriocins from Gram-positive bacteria. Biochimie 84, 545-57.
34. Strindhall, J., Lingren, P. E., Lofgren, S. et al. (2002). Variations among clinical isolates of Staphylococcus aureus to induce expression of E-selectin and ICAM-1 in human endothelial cells. FEMS Immunology and Medical Microbiology 32, 227-35.
35. Vaudaux, P. E., Monzillo, V., Francois, P. et al. (1998). Introduction of mec element (methicillin resistance) into Staphylococcus aureus alters in vitro functional activities of fibrinogen and fibronectin adhesions. Antimicrobial Agents and Chemotherapy 42, 564-70.
36. Kokai-Kun, J. F., Walsh, S. M., Chanturiya, T. et al. (2003). Lysostaphin cream eradicates Staphylococcus aureus nasal colonization in a cotton rat model. Antimicrobial Agents and Chemotherapy 47, 1589-97.